US investment bank Piper Jaffray recently released a report, predicting that Fluidigm's CyTOF mass spec platform will grow steadily in 2015. The CyTOF platform was originally developed by DVS Sciences, but this company was acquired by Fluidigm in February last year.
This forecast is based on Piper Jaffray's belief that the recognition of the CyTOF platform continues to increase, which is reflected in the significant increase in the number of references cited. In addition, Piper Jaffray also pointed out that existing customers purchase more instruments also represents a great opportunity for Fluidigm.
According to a report by Piper Jaffray, CyTOF has appeared in 54 published articles. Of these articles, 25 (46%) were published in 2014 and only 7 in 2013. Last year, there was also a leap in the number of research institutes using CyTOF to publish articles. A total of 15 different institutes published research that was supported by CyTOF, compared with only 6 in 2013.
Analysts wrote that these figures indicate that "CyTOF acceptance is improving." At the same time, according to the notion that institutions are more likely to purchase expensive instruments after widespread acceptance, the number of articles published in 2014 supported the 2015 CyTOF growth assumption.
Analysts added that existing customers with only one instrument also represented sales opportunities. They believe that these customers may increase the number of instruments. The earliest organizations currently have 7 CyTOF instruments, and 1 is on the road. In the third quarter of 2014, four existing customers purchased the second or third instrument. There are currently 65 customers with only one instrument. "There is still considerable room for expansion within the existing installation area," they write.
Overall, as of the third quarter of 2014, a total of 86 CyTOF instruments were installed worldwide. In addition, three units are expected to be delivered in the fourth quarter of 2014 and another three units will be delivered in the first quarter of 2015.
CyTOF combines the advantages of flow cytometry with the accuracy and resolution of mass spectrometry to enable multiparametric single-cell protein analysis. It uses metal element markers to label or identify signal molecules on the cell surface and inside, then separates individual cells by flow cytometry, and then observes the atomic mass spectra of individual cells using inductively coupled plasma mass spectrometry (ICP-MS), and finally atomically The mass spectrum of the data is converted to cell surface and internal signal molecule data. This platform is capable of quantifying up to 100 biomarkers in a single cell simultaneously.
In February 2014, Fluidigm acquired DVS Sciences Inc. and CyTOF Technology for $207.5 million, moving toward single-cell proteomics.
Although Piper Jaffray is optimistic about the sales of CyTOF in 2015, Fluidigm lowered its forecast for it in 2014, down from US$33-35 million to US$24-26 million, including 3.8 million that DVS has achieved before the acquisition. Dollar income. In the third quarter of 2014, the company revised its expectation again to USD 23-45 million.
Fluidigm also plans to begin selling a mass spectrometric flow imaging system using CyTOF technology in 2015.
Auxiliary Equipment,Cold Cutting Saw,Hydrauicl Uncoiler,Horizontal Accumulator,Computer Cutt Saw,Pneumatic Uncoiler,Manual Uncoiler
Yangzhou Donglun Industrial Equipment Co., Ltd , https://www.dltubemill.com